These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37386469)

  • 21. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Misdiagnosis of amyotrophic lateral sclerosis in clinical practice in Europe and the USA: a patient chart review and physician survey.
    Goyal NA; Bonar K; Savic N; Beau Lejdstrom R; Wright J; Mellor J; McDermott C
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):16-25. PubMed ID: 37794794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life and lifestyle changes in patients with chronic kidney disease and hyperkalaemia: Real-world data from the US, five European countries and China.
    Grandy S; Jackson J; Moon R; Bluff D; Palaka E
    Int J Clin Pract; 2021 Aug; 75(8):e14326. PubMed ID: 33960068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymectomy in the treatment of ocular myasthenia gravis.
    Roberts PF; Venuta F; Rendina E; De Giacomo T; Coloni GF; Follette DM; Richman DP; Benfield JR
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):562-8. PubMed ID: 11547310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administering Neostigmine as a Subcutaneous Infusion: A Case Report of a Patient Dying With Myasthenia Gravis.
    Hindmarsh J; Woods E; Lee M; Pickard J
    J Palliat Care; 2020 Apr; 35(2):78-81. PubMed ID: 31411109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in purely ocular myasthenia in Japan.
    Suzuki S; Murai H; Imai T; Nagane Y; Masuda M; Tsuda E; Konno S; Oji S; Nakane S; Motomura M; Suzuki N; Utsugisawa K
    BMC Neurol; 2014 Jul; 14():142. PubMed ID: 24996227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis.
    Gutierrez G; Girma H; Kuhnell P; Macaluso M; Kaminski HJ
    Ther Adv Rare Dis; 2022; 3():26330040221082673. PubMed ID: 37125217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey.
    Merola JF; Ogdie A; Gottlieb AB; Stein Gold L; Flower A; Jardon S; Klyachkin Y; Lebwohl M
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1329-1346. PubMed ID: 37183192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa.
    McCallion J; Borsi A; Noel W; Lee J; Karmous W; Sattler S; Boggia GM; Hardy EJ; Mitchell CR; Mitchell SA; Gilhus NE
    BMC Neurol; 2024 Feb; 24(1):61. PubMed ID: 38336636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey.
    Stenson K; O'Callaghan L; Mellor J; Wright J; Gibson G; Earl L; Barlow S; Fournier CN
    J Neurol Sci; 2023 Sep; 452():120764. PubMed ID: 37639764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
    Piehl F; Eriksson-Dufva A; Budzianowska A; Feresiadou A; Hansson W; Hietala MA; Håkansson I; Johansson R; Jons D; Kmezic I; Lindberg C; Lindh J; Lundin F; Nygren I; Punga AR; Press R; Samuelsson K; Sundström P; Wickberg O; Brauner S; Frisell T
    JAMA Neurol; 2022 Nov; 79(11):1105-1112. PubMed ID: 36121672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-National, Cross-Sectional Survey of Healthcare Resource Utilization in Patients with All Stages of Cognitive Impairment, Analyzed by Disease Severity, Country, and Geographical Region.
    Khandker RK; Ritchie CW; Black CM; Wood R; Jones E; Hu X; Ambegaonkar BM
    J Alzheimers Dis; 2020; 75(4):1141-1152. PubMed ID: 32390613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
    Ingram JR; Bettoli V; Espy JI; Kokolakis G; Martorell A; Villani AP; Wallinger H; Coak E; Kasparek T; Muscianisi E; Richardson C; Kimball AB
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1597-1605. PubMed ID: 35445469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Trial of Thymectomy in Myasthenia Gravis.
    Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
    N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.